| Date | Title | Description |
| 25.06.2026 | Definium Therapeutics Prices Upsized $700 Million Public Offering | Definium Therapeutics announced the pricing of an upsized underwritten public offering of 20,588,236 common shares at a public offering price of $34 per share.
The gross proceeds to Definium from the offering, before deducting underwriting ... |
| 14.06.2026 | Parabilis Medicines Closes Upsized IPO And Raises More Than $845 Million Including Regeneron Private Placement | Parabilis Medicines, a clinical-stage biopharmaceutical company focused on developing therapies against historically undruggable protein targets, announced the closing of its upsized initial public offering and a concurrent private placemen... |
| 11.08.2025 | Equillium: Up To $50 Million Financing Raised To Advance EQ504 | Equillium has secured a securities purchase agreement with leading healthcare investors to raise to $50 million. The financing includes an upfront payment of $30 million for approximately 52.6 million shares or pre-funded warrants at $0.57 ... |
| 03.05.2025 | Brainomix completes £14m Series C funding round | We are pleased to announce our latest investment in Brainomix, a University of Oxford spinout pioneering AI-powered imaging tools in stroke and lung fibrosis, as part of a £14m Series C funding round. The funding will support commercial exp... |
| 22.03.2025 | Brainomix: £14 Million (Series C) Closed For Advancing AI Imaging In Healthcare | Brainomix, a company pioneering AI-based imaging tools in stroke and lung fibrosis, announced the completion of a £14 million ($18 million) Series C investment round. The funding round was co-led by prominent healthtech investors that inclu... |
| 21.03.2025 | Brainomix Secures £14M to Revolutionize Stroke and Lung Fibrosis Treatment | In the fast-paced world of healthcare technology, Brainomix is making waves. The Oxford-based company has just raised £14 million in Series C funding. This investment is a lifeline, aimed at expanding its reach into the U.S. market. With a ... |
| 20.03.2025 | Brainomix secures €16.7 milllion to advance its AI imaging technology in healthcare | Oxford-based Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, today announced the completion of a €16.7 million Series C investment round to expand to the U.S.
The round is co-led by prominent HealthTech... |
| 10.02.2022 | Aeglea BioTherapeutics Announces Proposed Public Offering | AUSTIN, Texas, Feb. 9, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, tod... |